Approved Neurology Deal Benchmarks

Median Upfront

$2.2B

Range: $1.6B - $2.7B

Total Deal Value

$7.1B

Range: $5.8B - $8.4B

Royalty Rate

19.8% - 30%

Tiered up to 34.9%

Dev Milestones

$244M

Range: $213M - $283M

Model Your Deal

Market Analysis

Approved neurology licensing deals carry a median total deal value of $7.1B, with upfront payments ranging from $1.6B to $2.7B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 31% to upfront and 69% to milestones.

The neurology landscape at the approved stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $244M, regulatory milestones contribute $1.2B, and commercial milestones reach $3.4B. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for approved neurology deals range from 19.8% to 30% at the base tier, with high-tier escalation to 34.9%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for approved neurology deals?

Approved neurology deals average $2.2B in upfront payments, ranging from $1.6B to $2.7B. The upfront allocation of 31% of total deal value reflects the clinical stage risk profile.

How are approved neurology deal milestones structured?

Milestones account for approximately 69% of total deal value. Development milestones ($244M) represent the largest component, followed by commercial milestones ($3.4B) and regulatory milestones ($1.2B).

What royalty rates are typical for approved neurology licensing?

Base royalty rates range from 19.8% to 30%, with tiered escalation to 23.8%-34.9% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Approved Neurology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Neurology Deals

Phase 1 Neurology Deals

Approved Oncology Deals

Approved Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?